Home

Voják Odmítnout potrat event free survival overall strávit Disciplína atd

Event-Free Survival As a Surrogate Endpoint for Overall Survival in  Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level  Analysis of Multiple Randomized Trials (Alliance A151614) - ScienceDirect
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) - ScienceDirect

Kaplan-Meier plot of event-free survival (EFS) and overall survival... |  Download Scientific Diagram
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram

Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT  Handbook - NCBI Bookshelf
Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast  Cancer | NEJM
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM

Identification of potential surrogate end points in randomized clinical  trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of  complete response, time-to-event and overall survival end points - Annals  of Oncology
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology

Wilms tumour event-free and overall survival in Southern and Eastern  Europe: Pooled analyses of clinical data from four childhood cancer  registries (1999–2017) - European Journal of Cancer
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - European Journal of Cancer

Event-free survival at 24 months is a robust surrogate endpoint for  long-term survival in pediatric, adolescent, and adult T cell lymphoblastic  lymphoma | SpringerLink
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink

Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point,  Is Not a Surrogate for Overall Survival in Men With Localized Prostate  Cancer Treated With Radiation | Journal of Clinical Oncology
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology

Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival  as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal  Adenocarcinoma
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast  Cancer | NEJM
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM

View Image
View Image

Are progression-free and disease-free survival the new gold standard for  cancer trials? | Cancer World Archive
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive

A) Event-free survival (EFS), (B) disease-free survival (DFS), and (C)... |  Download Scientific Diagram
A) Event-free survival (EFS), (B) disease-free survival (DFS), and (C)... | Download Scientific Diagram

OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND  10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases

Identification of potential surrogate end points in randomized clinical  trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of  complete response, time-to-event and overall survival end points - Annals  of Oncology
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology

Event-free survival and overall survival (A) Event-free survival for... |  Download Scientific Diagram
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram

Acute myeloid leukemia: survival analysis of patients at a university  hospital of Paraná | Hematology, Transfusion and Cell Therapy
Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy

A prognostic nomogram for event-free survival in patients with atrial  fibrillation before cardiac resynchronization therapy | BMC Cardiovascular  Disorders | Full Text
A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text

Cureus | Does Timing of Completion Radical Cholecystectomy Determine the  Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center  Retrospective Analysis
Cureus | Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center Retrospective Analysis

A correlation analysis to assess event-free survival as a trial-level  surrogate for overall survival in early breast cancer - eClinicalMedicine
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine

JCI - Umbilical cord blood expansion with nicotinamide provides long-term  multilineage engraftment
JCI - Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is  associated with sustained worse outcome compared with docetaxel,  anthracycline and cyclophosphamide in neoadjuvant treatment of triple  negative and HER2-positive breast cancer ...
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer ...